Rhythm Pharmaceuticals Inc’s recent filing unveils that its Chief Financial Officer Smith Hunter C unloaded Company’s shares for reported $0.13 million on Feb 19 ’25. In the deal valued at $57.22 per share,2,215 shares were sold. As a result of this transaction, Smith Hunter C now holds 109,929 shares worth roughly $5.5 million.
Then, Shulman Joseph sold 1,228 shares, generating $70,266 in total proceeds. Upon selling the shares at $57.22, the Chief Technical Officer now owns 8,509 shares.
Before that, Meeker David P sold 9,896 shares. Rhythm Pharmaceuticals Inc shares valued at $566,249 were divested by the President and CEO at a price of $57.22 per share. As a result of the transaction, Meeker David P now holds 201,281 shares, worth roughly $10.08 million.
A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. Oppenheimer began covering RYTM with “an Outperform” recommendation on December 20, 2024. Guggenheim started covering the stock on October 21, 2024. It rated RYTM as “a Buy”.
Price Performance Review of RYTM
On Tuesday, Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] saw its stock jump 3.09% to $50.06. Over the last five days, the stock has lost -5.94%. Rhythm Pharmaceuticals Inc shares have fallen nearly -10.58% since the year began. Nevertheless, the stocks have risen 20.13% over the past one year. While a 52-week high of $68.58 was reached on 02/05/25, a 52-week low of $35.17 was recorded on 03/10/25. SMA at 50 days reached $56.25, while 200 days put it at $51.12.
Levels Of Support And Resistance For RYTM Stock
The 24-hour chart illustrates a support level at 48.43, which if violated will result in even more drops to 46.80. On the upside, there is a resistance level at 51.16. A further resistance level may holdings at 52.25. The Relative Strength Index (RSI) on the 14-day chart is 36.81, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.08, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 79.23%. Stochastics %K at 11.81% indicates the stock is a buying.
The most recent change occurred on September 18, 2024 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $64 price target.
